Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

FHS
July 11, 2023
11:31 am

NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, today announced it has been awarded £1.6M in grant funding from Innovate UK’s New Cancer Therapeutics program.

Vaping linked to respiratory issues in young adults

Researchers explore the association of respiratory illness based on self-reported symptoms among young adolescents who vaped.

May 31, 2024

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology – Biotech Investments

EQS-News: invIOs GmbH / Key word(s): Financing invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology 15.10.2024 / 10:30 CET/CEST

October 16, 2024

Dexcom shares plunge on lower sales outlook

By the numbers Q2 revenue: $1 billion 15% increase year-over-year Net income: $143.5 million About 24% increase year-over-year 2024 forecast: Organic sales growth of 11%

July 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.